VRCA Verrica Pharmaceuticals Inc.

4.140USD-1.66%Mkt Cap: 71.12M $P/E: —

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH…

Key Statistics

Company
Market Cap71.12M USD
Enterprise Value62.93M USD
Revenue (TTM)30.32M USD
Gross Profit32.14M USD
Net Income (TTM)-17.89M USD
Revenue/Share1.83 USD
Last Price4.140 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.85
PEG—
EV/EBITDA-2.42
EV/Revenue2.08
P/S2.39
P/B16.77
EPS (TTM)-1.75
EPS (Forward)-1.48
52W Range
3.28013% of range9.821
52W High9.821 USD
52W Low3.280 USD
Profitability
Gross Margin90.33%
Oper. Margin-194.46%
EBITDA Margin-85.63%
Profit Margin-50.27%
ROE-72.29%
ROA-37.95%
Growth
Revenue Growth-53.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.63M USD
CapEx (TTM)—
FCF Margin-29.80%
FCF Yield-12.71%
Net Debt-9.39M USD
Net Debt/EBITDA0.36
Balance Sheet
Debt/Equity0.07
Current Ratio1.45
Quick Ratio0.99
Book Value/Sh0.25 USD
Cash/Share0.65 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 25, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.83 USD
Upside (mean)+234.1%
Target Range9.000 USD – 20.00 USD
9.000+234.1% to mean20.00
# Analysts6
Ownership
Shares Out.17.18M
Float12.41M
Insiders49.00%
Institutions27.14%
Short Interest
Short Ratio1.9d
Short % Float2.30%
Short % Out.1.18%
Shares Short202.75K
Short (prev mo.)269.35K
Technical
SMA 504.951 (-16.4%)
SMA 2006.028 (-31.3%)
Beta1.61
S&P 52W Chg16.45%
Avg Vol (30d)68.86K
Avg Vol (10d)44.07K
Technical Indicators
RSI (14)36.3
MACD-0.2330
MACD Signal-0.2055
MACD Hist.-0.0275
BB Upper5.298 USD
BB Middle4.638 USD
BB Lower3.979 USD
BB Width28.45%
ATR (14)0.3285 USD
Vol Ratio (20d)0.94x